Scleroderma Clinical Trials Consortium

Advancing research for people with scleroderma

Welcome to the Scleroderma Clinical Trials Consortium (SCTC)

The Scleroderma Clinical Trials Consortium (SCTC) is a global network of researchers and healthcare professionals who have a particular interest and expertise in the care of, and research in, scleroderma (systemic sclerosis). Our mission is to enhance the development, execution, and analysis of clinical trials to improve treatment options and outcomes for patients with scleroderma worldwide.

At a glance

The 2026 Request for Grant Applications for the SCTC Working Groups is now OPEN!

Upcoming Meeting(s)

SCTC Spring Roundtable Meeting 2026 – Nashville, Tennessee

Join us for the 2026 SCTC Spring Roundtable Meeting for Industry Partners, an exclusive in-person event in Nashville, bringing together key stakeholders in scleroderma research and clinical trials.

Date: 01/05/2026

SCTC Working Groups

Our Working Groups are designed to focus discussion and establish collaborative research projects aimed at increasing the efficiency of clinical trials and observational studies or producing position papers representative of the opinions of a majority of our SCTC members.

Participate in our ongoing working groups

Learn about current research initiatives and find out how you can support and contribute to advancing scientific progress.

Our Working Groups

Our Mission

At SCTC, we are committed to:

Advancing Clinical Research:
Collaborating with experts worldwide to design and conduct high-quality clinical trials.
Developing Standardized Outcome Measures:
Ensuring consistency in clinical trial assessments to facilitate better treatment evaluation.
Enhancing Patient Care:
Supporting research that leads to improved diagnosis, treatment, and quality of life for individuals with scleroderma.
Education and Training:
Providing opportunities for researchers, clinicians, and early-career investigators to contribute to and learn from cutting-edge research.

Advancing standards of research for people with scleroderma by conducting, sponsoring, and facilitating projects that improve clinical outcomes with a special focus on clinical trials.

Why Scleroderma research matters

Scleroderma is a complex and rare autoimmune disease that affects the skin and internal organs, leading to severe complications, with limited treatment options. Through rigorous clinical research, we aim to uncover new therapies, refine treatment guidelines, and ultimately improve patient outcomes.

Our Work

Collaborative Research Initiatives:
Bringing together specialists to develop groundbreaking research with a focus on innovative clinical trial methodologies.
Patient-Centered Studies:
Ensuring that research focuses on meaningful outcomes for individuals living with scleroderma.
Global Partnerships:
Working with international organizations, institutions, and industry leaders to accelerate discoveries in scleroderma research.

Together, we can make a difference in the lives of those affected by scleroderma.

Get involved

You can contribute to scleroderma research in several ways: